Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors
Incannex Healthcare (Nasdaq: IXHL) has secured a strategic financing deal with Arena Investors for up to $60 million. The agreement includes up to $10 million in secured convertible notes and a $50 million equity line of credit (ELOC). The initial funding tranche of $3.33 million will be received upon closing, with two subsequent tranches available up to $6.67 million. The ELOC allows Incannex to issue and sell up to $50 million of common stock over 36 months.
Incannex plans to use the funds to support ongoing clinical trials of its proprietary drug candidates, including IHL-42X for obstructive sleep apnea, PsiGAD for generalized anxiety disorder, and IHL-675A for rheumatoid arthritis. This financing strengthens Incannex's ability to advance its lead programs through key late-stage clinical milestones.
Incannex Healthcare (Nasdaq: IXHL) ha concluso un accordo di finanziamento strategico con Arena Investors per un massimo di 60 milioni di dollari. L'accordo include fino a 10 milioni di dollari in note convertibili garantite e una linea di credito azionaria di 50 milioni di dollari (ELOC). La tranche iniziale di finanziamento di 3,33 milioni di dollari sarà ricevuta al momento della chiusura, con due tranche successive disponibili fino a 6,67 milioni di dollari. L'ELOC consente a Incannex di emettere e vendere fino a 50 milioni di dollari di azioni ordinarie in un arco di 36 mesi.
Incannex prevede di utilizzare i fondi per sostenere le clinical trial in corso dei suoi farmaci proprietari, inclusi IHL-42X per l'apnea ostruttiva del sonno, PsiGAD per il disturbo d'ansia generalizzato e IHL-675A per l'artrite reumatoide. Questo finanziamento rafforza la capacità di Incannex di far avanzare i suoi programmi di punta attraverso importanti traguardi clinici in fase avanzata.
Incannex Healthcare (Nasdaq: IXHL) ha asegurado un acuerdo de financiación estratégica con Arena Investors por hasta 60 millones de dólares. El acuerdo incluye hasta 10 millones de dólares en notas convertibles garantizadas y una línea de crédito de 50 millones de dólares (ELOC). La tranche inicial de financiación de 3,33 millones de dólares se recibirá al cierre, con dos tranches posteriores disponibles de hasta 6,67 millones de dólares. La ELOC permite a Incannex emitir y vender hasta 50 millones de dólares en acciones ordinarias durante 36 meses.
Incannex planea utilizar los fondos para apoyar los ensayos clínicos en curso de sus candidatos a medicamentos patentados, que incluyen IHL-42X para la apnea obstructiva del sueño, PsiGAD para el trastorno de ansiedad generalizada y IHL-675A para la artritis reumatoide. Este financiamiento refuerza la capacidad de Incannex para avanzar en sus programas principales a través de hitos clínicos clave en etapas avanzadas.
Incannex Healthcare (Nasdaq: IXHL)는 Arena Investors와 함께 최대 6000만 달러 규모의 전략적 금융 거래를 체결했습니다. 이 계약에는 최대 1000만 달러의 담보 전환사채와 5000만 달러의 주식 신용 한도 (ELOC)가 포함됩니다. 333만 달러의 초기 자금 이체가 종료 시 수령되며, 이후 두 차례에 걸쳐 667만 달러까지 제공됩니다. ELOC를 통해 Incannex는 36개월 동안 최대 5000만 달러의 보통주를 발행 및 판매할 수 있습니다.
Incannex는 자금을 사용하여 IHL-42X 폐쇄성 수면무호흡증, PsiGAD 범불안장애, IHL-675A 류마티스 관절염과 같은 자사의 독점 약물 후보의 ongoing clinical trials를 지원할 계획입니다. 이 자금 조달은 Incannex가 주요 후기 단계 임상 이정표를 통해 선도 프로그램을 발전시킬 수 있는 능력을 강화합니다.
Incannex Healthcare (Nasdaq: IXHL) a sécurisé un accord de financement stratégique avec Arena Investors pour un montant pouvant atteindre 60 millions de dollars. L'accord comprend jusqu'à 10 millions de dollars en obligations convertibles sécurisées et une ligne de crédit par actions de 50 millions de dollars (ELOC). La première tranche de financement de 3,33 millions de dollars sera reçue lors de la clôture, avec deux tranches supplémentaires disponibles jusqu'à 6,67 millions de dollars. L'ELOC permet à Incannex d'émettre et de vendre jusqu'à 50 millions de dollars d'actions ordinaires sur 36 mois.
Incannex prévoit d'utiliser les fonds pour soutenir les essais cliniques en cours de ses candidats médicaments exclusifs, notamment IHL-42X pour l'apnée obstructive du sommeil, PsiGAD pour le trouble d'anxiété généralisée et IHL-675A pour l'arthrite rhumatoïde. Ce financement renforce la capacité d'Incannex à faire avancer ses programmes phares à travers des étapes cliniques clés en phase avancée.
Incannex Healthcare (Nasdaq: IXHL) hat eine strategische Finanzierungsvereinbarung mit Arena Investors über bis zu 60 Millionen Dollar gesichert. Die Vereinbarung umfasst bis zu 10 Millionen Dollar in gesicherten Wandelanleihen und eine Eigenkapitalkreditlinie von 50 Millionen Dollar (ELOC). Die erste Finanzierungsrate von 3,33 Millionen Dollar wird bei Abschluss erhalten, mit zwei nachfolgenden Tranchen von bis zu 6,67 Millionen Dollar. Die ELOC ermöglicht es Incannex, über einen Zeitraum von 36 Monaten bis zu 50 Millionen Dollar an Stammaktien auszugeben und zu verkaufen.
Incannex plant, die Mittel zu verwenden, um laufende klinische Studien seiner proprietären Arzneimittelkandidaten zu unterstützen, darunter IHL-42X bei obstruktiver Schlafapnoe, PsiGAD bei generalisierter Angststörung und IHL-675A bei rheumatoider Arthritis. Diese Finanzierung stärkt die Fähigkeit von Incannex, seine wichtigsten Programme durch entscheidende klinische Meilensteine in späten Phasen voranzutreiben.
- Secured up to $60 million in strategic financing
- Initial funding of $3.33 million available upon closing
- Flexibility to access additional $6.67 million in convertible notes
- $50 million equity line of credit available over 36 months
- Funds to support ongoing clinical trials for multiple drug candidates
- 10% original issue discount on convertible notes
- Potential dilution of existing shareholders through ELOC
This strategic financing deal is a significant development for Incannex Healthcare. The
The 10% original issue discount on the convertible notes is worth noting, as it increases the effective cost of capital. Investors should closely monitor the conversion terms and their potential impact on share price. The ELOC's 36-month duration provides a lengthy runway for funding, but its utilization and impact on share price will depend on market conditions and the company's clinical progress.
Overall, this deal strengthens Incannex's financial position, supporting its ambitious clinical trial program. However, the potential for dilution and the terms of conversion warrant careful investor attention.
Incannex's strategic financing is important for advancing its diverse clinical pipeline. The company's focus on three key programs demonstrates a balanced approach to drug development:
- IHL-42X for obstructive sleep apnea (Phase 2/3)
- PsiGAD for generalized anxiety disorder (Phase 2)
- IHL-675A for rheumatoid arthritis (Phase 2)
This funding could accelerate these trials, potentially leading to faster market entry if successful. The variety of indications targeted - from sleep disorders to mental health and autoimmune conditions - spreads risk and increases the chances of at least one successful product.
Investors should monitor the progress of these trials closely, as positive results could significantly impact Incannex's valuation. However, it's important to remember that clinical trials, especially in later phases, carry substantial risks and costs.
Incannex to Receive Funding of Up to
NEW YORK and MELBOURNE, Australia, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (the “Company” or “Incannex”), a clinical-stage biopharmaceutical company developing life-changing medicines for people with chronic diseases and significant unmet medical needs, today announced it has entered into an agreement to issue up to
“We are pleased to be partnering with Arena and ABS on this strategic financing, which strengthens Incannex’s ability to advance our lead programs through key late-stage clinical milestones,” said Joel Latham, Incannex’s President and Chief Executive Officer. “We look forward to updating investors on our progress, including progressing IHL-42X through Phase 2/3 trials for the treatment of obstructive sleep apnea, PsiGAD through a Phase 2 study for generalized anxiety disorder, and IHL-675A through a Phase 2 trial for rheumatoid arthritis.”
Incannex intends to use the proceeds from the strategic financing to support the ongoing clinical trials of the Company’s proprietary drug candidates, and for working capital and other general corporate purposes. Incannex will determine allocation of funds according to the company’s strategic needs. The initial funding tranche of
Further information regarding the Securities Purchase Agreement and the ELOC Agreement are provided in the Current Report on Form 8-K filed today with the Securities and Exchange Commission.
About Arena Investors, LP
Arena is an institutional asset manager founded in partnership with The Westaim Corporation (TSXV: WED). With
About Incannex Healthcare Inc.
Incannex is a clinical-stage biopharmaceutical development company focused on developing innovative medicines for patients living with chronic diseases and significant unmet need. With three programs currently in Phase 2/3 and Phase 2 development, Incannex is advancing proprietary, synthetic first- and best-in-class cannabinoid and psychedelic-assisted therapeutics targeting sleep apnea, anxiety, and inflammatory diseases. Incannex’s lead programs include IHL-42X for the treatment of obstructive sleep apnea (OSA), Psi-GAD in development to assess the use of psilocybin-assisted therapy for generalized anxiety disorder, and IHL-675A in Phase 2 trials for rheumatoid arthritis. Each of these programs target conditions for which there are either no approved treatments or the available treatments are inadequate. For further information, please visit www.incannex.com.
Forward-looking statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations and estimates, as well as the beliefs and assumptions of management. The forward-looking statements included in this press release represent Incannex's views as of the date of this press release. Incannex anticipates that subsequent events and developments may cause its views to change. Incannex undertakes no intention or obligation to update or revise any forward-looking statements, whether as of a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Incannex's views as of any date after the date of this press release.
Not an offer of securities
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this press release have not been, and will not be, registered under the Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the Securities Act and applicable state securities laws.
Contact Information:
Incannex Healthcare Inc.
Joel Latham
President and CEO
investors@incannex.com.au
Investor Relations Contact – United States
Jennifer Drew-Bear
Edison Group
Jdrew-bear@edisongroup.com
Arena Investors, LP
Parag Shah
ir@arenaco.com
FAQ
What is the total value of Incannex Healthcare's (IXHL) new financing agreement with Arena Investors?
How much initial funding will Incannex Healthcare (IXHL) receive from the financing agreement?
What clinical trials will Incannex Healthcare (IXHL) support with the new financing?
How long is the equity line of credit (ELOC) available to Incannex Healthcare (IXHL)?
